(19)
(11) EP 2 954 068 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
31.10.2018 Bulletin 2018/44

(45) Mention of the grant of the patent:
05.09.2018 Bulletin 2018/36

(21) Application number: 14706699.7

(22) Date of filing: 04.02.2014
(51) International Patent Classification (IPC): 
C12Q 1/68(2018.01)
(86) International application number:
PCT/IB2014/058790
(87) International publication number:
WO 2014/122582 (14.08.2014 Gazette 2014/33)

(54)

DRUG SELECTION FOR NON-SMALL CELL LUNG CANCER THERAPY

WIRKSTOFFAUSWAHL FÜR EINE THERAPIE GEGEN NICHT-KLEINZELLIGEN LUNGENKREBS

SÉLECTION D'UN MÉDICAMENT POUR UNE THÉRAPIE ANTICANCÉREUSE DU CANCER DU POUMON NON À PETITES CELLULES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 05.02.2013 US 201361761105 P

(43) Date of publication of application:
16.12.2015 Bulletin 2015/51

(73) Proprietor: Pierian Holdings, Inc.
Franklin, TN 37067 (US)

(72) Inventors:
  • SINGH, Sharat
    Rancho Santa Fe California 92127 (US)
  • KIM, Phillip
    Irvine California 92612 (US)
  • LOCKTON, Steven
    San Diego California 92121 (US)

(74) Representative: J A Kemp 
14 South Square Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB)


(56) References cited: : 
WO-A1-2011/008990
WO-A2-2012/119113
 WO-A1-2012/088337
   
  • N HOE ET AL: "Selection of targeted agent(s) based on matching differential protein expression and mutational profile in NSCLC patients.", JOURNAL OF CLINICAL ONCOLOGY, vol. 29, no. 15_suppl, 20 May 2011 (2011-05-20), page e21085, XP055020717,
  • HUA C. GONG ET AL: "Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer", INTERNATIONAL JOURNAL OF PROTEOMICS, vol. 2011, 1 January 2011 (2011-01-01), pages 1-13, XP055030274, ISSN: 2090-2166, DOI: 10.1155/2011/215496
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).